Inventiva-2026-JPM.pdf

1、Property of InventivaAdvancing Lanifibranor:Potential Best-in-Disease Oral Therapy for MASHA DIFFERENTIATED ORAL ANTIFIBROTIC CANDIDATE DESIGNED TO ADDRESS PROGRESSIVE FIBROSIS IN F2/F3 MASHJ.P.Morgan Healthcare Conference 2026Property of InventivaCorporate PresentationDisclaimerThis presentation co

2、ntains“forward-looking statements”within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.All statements,other than statements of historical facts,included in thispresentation are forward-looking statements.These statements include,but are not limited

3、 to,forecasts and estimates with respect to Inventivas clinical trials,including the design,duration,timing,costs and results thereof and regulatorymatters with respect thereto,the information,insights and impacts that may be gathered from clinical trials,the potential therapeutic benefits of lanifi

4、branor,the potential of lanifibranor to address patient needs,including expectations regardinglanifibranors efficacy and safety profile,market forecasts including with respect to products developed by other companies,estimates of addressable markets,including the growing demand and urgency for MASH

5、treatments,targeteddevelopment,potential regulatory submission,approval and commercialization,including their anticipated timelines,Inventivas pipeline and clinical development plans,the opportunity for lanifibranor based on the current clinical program,futureactivities,expectations,plans,growth and

6、 prospects of Inventiva,forecasts and estimates with respect to Inventivas estimated cash runway,the potential exercise of warrants and pre-funded warrants,including the securities issued inconnection with Inventivas multi-tranche equity financing announced on October 14,2024(the“Structured Financin